Growth Hormone

A selective growth hormone secretagogue and ghrelin receptor agonist that stimulates pulsatile GH release with minimal effect on cortisol or prolactin.

A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.

An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.

A non-peptide, orally active ghrelin receptor agonist that raises growth hormone and IGF-1. Completed but did not pass Phase 3 for approval.

A GHRH fragment historically approved as a diagnostic and pediatric GH agent, now used in compounded anti-aging research.

An early GH secretagogue hexapeptide that strongly stimulates growth hormone and appetite.

A long-acting analogue of IGF-1 studied in animal models for muscle growth and tissue repair.

A potent synthetic GH-releasing hexapeptide studied for growth hormone release and direct cardioprotective effects.

A second-generation GH secretagogue approved in Japan as a diagnostic agent, producing strong GH release with less appetite effect than GHRP-6.

The body's own hunger hormone and the natural trigger for growth hormone release, and the template for the entire GHRP peptide class.

An early synthetic growth hormone releasing peptide, part of the first generation that established the GHRP class.

FDA-approved recombinant human growth hormone used for growth hormone deficiency and several other approved indications.

The natural hormone that switches off growth hormone release; its analogues like octreotide are approved drugs.